CRC
ELDN icon

Curi RMB Capital’s Eledon Pharmaceuticals ELDN Stock Holding History

Curi RMB Capital’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$13.7K – 514
2023
Q3 		$13.7K Buy
+10,000
New +$13.3K ﹤0.01% 495

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JE
JMAC Enterprises Newtown, Pennsylvania $593M AUM 22.22% 1-Year Est. Return

Curi RMB Capital's ELDN Position: Q4 2023 in Review

Curi RMB Capital sold out of Eledon Pharmaceuticals (ELDN) in Q4 2023, closing a stake of 10,000 shares — an estimated $13.7K sold.

Curi RMB Capital first reported a position in ELDN in Q3 2023 and held it in 1 quarter. The position peaked at $13.7K in Q3 2023. 29 funds tracked by Wall St. Rank hold ELDN as of Q4 2023.

  • Curi RMB Capital reported no remaining Eledon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Curi RMB Capital sold 10,000 Eledon Pharmaceuticals shares in Q4 2023, an estimated $13.7K.
  • Curi RMB Capital first reported a position in Eledon Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Curi RMB Capital's Eledon Pharmaceuticals position peaked at $13.7K in Q3 2023.
  • 29 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2023.

Based on Curi RMB Capital's 13F filing for Q4 2023, filed 14 Feb 2024.